Small Molecule Anti-Angiogenic Compounds for Diabetic Retinopathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases characterized by inappropriate growth of new blood vessels, such as diabetic retinopathy, age-related macular degeneration, and cancer, are limited by the need for frequent and costly injections, potential toxicity, and the development of resistance to anti-angiogenic therapies.
Innovation Solution
A pharmaceutical composition comprising specific compounds with a six-membered heteroaryl ring and an alkyne or alkene linkage, which can be administered topically or systemically to inhibit angiogenesis, potentially offering a safer, more cost-effective alternative to existing therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies or decoy receptors are used to attenuate VEGF signaling, then anti-angiogenic activity is improved, but treatment cost and manufacturing complexity increase significantly
Solution Approach 1:
The patent replaces expensive monoclonal antibodies with small molecule compounds that can be synthesized more cheaply and administered more frequently. These smaller molecules are less costly to manufacture but may require more frequent dosing to maintain therapeutic effect, embodying the trade-off of using cheaper, shorter-acting agents instead of expensive, long-acting biologics
Solution Approach 2:
The invention changes the molecular parameters from large protein-based therapeutics (monoclonal antibodies) to small organic molecules with specific heteroaryl ring structures. This parameter change enables different administration routes and reduces manufacturing complexity while maintaining anti-angiogenic efficacy through structural optimization of the small molecule compounds
2Reliability
If monoclonal antibodies or decoy receptors are administered intravitreally, then anti-angiogenic efficacy is improved, but treatment frequency and patient burden increase due to monthly injections
Solution Approach 1:
The small molecule compounds have shorter half-lives requiring more frequent administration, but this enables use of simpler administration routes (topical, oral, or intravitreal) rather than requiring complex monthly intravitreal injections, potentially improving patient compliance despite increased frequency
Solution Approach 2:
The patent enables administration routes that patients or non-specialist personnel can perform (such as topical application or oral administration) rather than requiring specialized ophthalmological procedures, allowing the treatment to serve itself without requiring retinal specialists for each administration
3Reliability
If laser ablation is used to destroy new vessels in diabetic retinopathy, then new vessel growth is inhibited, but retinal damage occurs at the treatment site
Solution Approach 1:
The patent introduces small molecule compounds as chemical intermediaries that systematically inhibit angiogenesis throughout the retina rather than using physical laser energy that locally destroys tissue. These molecules act as mediators between the therapeutic goal and the biological target, providing diffuse inhibition without focal thermal damage
Solution Approach 2:
The invention replaces the mechanical/thermal laser ablation system with a chemical pharmacological system. Instead of using laser energy to physically destroy vessels, small molecule compounds chemically inhibit the angiogenic process, substituting a mechanical destruction approach with a biochemical inhibition approach that avoids thermal damage
4Reliability
If anti-angiogenic therapy is used to treat cancer, then tumor growth is initially inhibited, but resistance develops and tumour growth is restored over time
Solution Approach 1:
The patent describes compounds with multiple heteroaryl ring structures that may target multiple aspects of the angiogenic pathway simultaneously. This multi-functionality could address resistance by hitting multiple targets in the angiogenic cascade, preventing single-point failures that lead to resistance development
Solution Approach 2:
The small molecule compounds incorporate multiple heteroaryl ring moieties (pyridine, pyrimidine, triazine, etc.) within single molecular structures, creating composite molecular architectures that may engage multiple biological targets or pathways, thereby extending therapeutic duration by preventing resistance through multi-target engagement
Data Source
AI summary
Compounds and compositions are described which are useful especially for treatment of angiogenesis-related diseases or disorders such as neovascularisation of the eye, age-related macular degeneration, diabetic retinopathy or cancer.